Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Details
Account Type
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commission
0.1%
Trading schedule (UTC)
Open NowClosed NowCloses onOpening on
at
-
This shows the opening hours in your local time zone
(UTC)
Open an account and start investing with Metadoro now. Invite friends and get rewarded for their active trading. You can learn more about the affiliate program in your personal account.
Thank you for visiting metadoro.com. This website is managed by RHC Investments, which is authorised and regulated as an Investment Dealer by the Financial Services Commission of Mauritius with License number C115015381. Mauritius is not part of the European regulatory framework and is not in scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you confirm that the decision is made independently and at your own exclusive initiative and that no solicitation or recommendation has been made by RHC Investments.
Create a NewsletterCreate a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Discover timely market up-and-downs, pumps, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found